Date Filed | Type | Description |
01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/10/2023 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 11 shares
@ $1.3, valued at
$14.3 |
|
01/04/2023 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 5 shares
@ $1.89, valued at
$9.5 |
|
12/08/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 9 shares
@ $2.02, valued at
$18.2 |
|
12/02/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 5 shares
@ $2.25, valued at
$11.3 |
|
11/08/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 10 shares
@ $2.2392, valued at
$22.4 |
|
11/01/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 5 shares
@ $2.54, valued at
$12.7 |
|
10/11/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 9 shares
@ $2.72, valued at
$24.5 |
|
10/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/07/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 225 shares
@ $0.1566, valued at
$35.2 |
|
09/01/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 107 shares
@ $0.1646, valued at
$17.6 |
|
08/15/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Exercised 239,800 options to buy
@ $0.45, valued at
$107.9k
Exercised 119,900 restricted stock units
@ $0 Exercised 239,800 rights
@ $0.45, valued at
$107.9k
Exercised 119,900 options to buy
@ $0 |
|
08/08/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 225 shares
@ $0.1847, valued at
$41.6 |
|
08/03/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 107 shares
@ $0.179, valued at
$19.2 |
|
07/07/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 225 shares
@ $0.1822, valued at
$41 |
|
07/01/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 107 shares
@ $0.182, valued at
$19.5 |
|
06/24/2022 |
4
| Schroeder Theodore R (Director) has filed a Form 4 on Cidara Therapeutics, Inc.
Txns:
| Granted 28,000 options to buy
@ $0.53, valued at
$14.8k
|
|
06/23/2022 |
4
| Schroeder Theodore R (Director) has filed a Form 4 on OTONOMY, INC.
Txns:
| Granted 27,500 options to buy
@ $1.95, valued at
$53.6k
|
|
06/07/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 225 shares
@ $0.2, valued at
$45 |
|
06/02/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 107 shares
@ $0.2066, valued at
$22.1 |
|
05/09/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 225 shares
@ $0.26, valued at
$58.5 |
|
05/03/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 107 shares
@ $0.31, valued at
$33.2 |
|
04/08/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 219 shares
@ $0.41, valued at
$89.8 |
|
04/04/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 104 shares
@ $0.42, valued at
$43.7 |
|
03/08/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 263 shares
@ $0.43, valued at
$113.1 |
|
03/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/01/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 10,766 shares
@ $0.45, valued at
$4.8k
Paid exercise price by delivering 125 shares
@ $0.48, valued at
$60 |
|
02/01/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Granted 239,800 options to buy
@ $0.45, valued at
$107.9k
Granted 119,900 restricted stock units
@ $0 |
|
01/10/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 270 shares
@ $0.58, valued at
$156.6 |
|
01/04/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 107 shares
@ $0.6, valued at
$64.2 |
|
12/29/2021 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Bought 100,000 shares
@ $0.5732, valued at
$57.3k
|
|
12/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|